PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23170931-13 2013 CONCLUSIONS: The combination of colesevelam with rosuvastatin 5 mg/day may be associated with favorable effects on markers of insulin resistance compared with rosuvastatin 10 mg/day in patients with hypercholesterolemia and IFG. Rosuvastatin Calcium 49-61 insulin Homo sapiens 126-133 34086261-9 2021 However, only in metformin-naive men, rosuvastatin increased LH and FSH levels and slightly impaired insulin sensitivity. Rosuvastatin Calcium 38-50 insulin Homo sapiens 101-108 30651799-10 2019 For patients with type 2 diabetes mellitus and coronary heart disease, treatment with rosuvastatin can effectively lower the level of blood lipid and regulate insulin functions; moreover, potent decrease in blood lipid level has great significance in improving the vascular endothelial functions and reducing inflammatory response levels. Rosuvastatin Calcium 86-98 insulin Homo sapiens 159-166 27544612-0 2016 Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Rosuvastatin Calcium 0-12 insulin Homo sapiens 98-105 27544612-5 2016 Rosuvastatin 5,10, and 20mg dose-dependently and significantly increased insulin (mean % changes; 19, 29, and 31%, respectively) and glycated hemoglobin levels (mean % changes; 2, 2, and 3%, respectively), and decreased adiponectin levels (mean % changes; 3, 9, and 14%, respectively) and insulin sensitivity (mean % changes; 2, 3, and 4%, respectively) after 2months therapy when compared with baseline (all P<0.05 by paired t-test). Rosuvastatin Calcium 0-12 insulin Homo sapiens 73-80 27544612-5 2016 Rosuvastatin 5,10, and 20mg dose-dependently and significantly increased insulin (mean % changes; 19, 29, and 31%, respectively) and glycated hemoglobin levels (mean % changes; 2, 2, and 3%, respectively), and decreased adiponectin levels (mean % changes; 3, 9, and 14%, respectively) and insulin sensitivity (mean % changes; 2, 3, and 4%, respectively) after 2months therapy when compared with baseline (all P<0.05 by paired t-test). Rosuvastatin Calcium 0-12 insulin Homo sapiens 289-296 27544612-6 2016 These effects with rosuvastatin 5, 10, and 20mg were significant when compared with placebo (P=0.006 for insulin, P=0.012 for glycated hemoglobin, P=0.007 for adiponectin, and P=0.002 for insulin sensitivity by ANOVA). Rosuvastatin Calcium 19-31 insulin Homo sapiens 105-112 27544612-6 2016 These effects with rosuvastatin 5, 10, and 20mg were significant when compared with placebo (P=0.006 for insulin, P=0.012 for glycated hemoglobin, P=0.007 for adiponectin, and P=0.002 for insulin sensitivity by ANOVA). Rosuvastatin Calcium 19-31 insulin Homo sapiens 188-195 27544612-7 2016 CONCLUSIONS: Despite beneficial reductions in LDL cholesterol and improvement of flow-mediated dilation, rosuvastatin dose-dependently and significantly resulted in decreasing insulin sensitivity and increasing ambient glycemia by reducing adiponectin levels and increasing insulin levels in hypercholesterolemic patients. Rosuvastatin Calcium 105-117 insulin Homo sapiens 176-183 27544612-7 2016 CONCLUSIONS: Despite beneficial reductions in LDL cholesterol and improvement of flow-mediated dilation, rosuvastatin dose-dependently and significantly resulted in decreasing insulin sensitivity and increasing ambient glycemia by reducing adiponectin levels and increasing insulin levels in hypercholesterolemic patients. Rosuvastatin Calcium 105-117 insulin Homo sapiens 274-281 26157049-0 2015 Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. Rosuvastatin Calcium 0-12 insulin Homo sapiens 21-28 26157049-7 2015 Compared with placebo, rosuvastatin therapy was associated with significantly greater increases in insulin and HOMA-IR (P = .008 and P = .004, respectively). Rosuvastatin Calcium 23-35 insulin Homo sapiens 99-106 25686680-12 2015 Within the rosuvastatin group, changes in NT-proBNP were negatively correlated with changes in insulin resistance and total limb fat. Rosuvastatin Calcium 11-23 insulin Homo sapiens 95-102 22204857-1 2013 BACKGROUND: Rosuvastatin and pravastatin have differential hydrophilicity and potency to inhibit hydroxymethylglutaryl-CoA reductase that may be relevant to changes in adiponectin levels, insulin resistance, and the rate of new onset diabetes in large clinical studies. Rosuvastatin Calcium 12-24 insulin Homo sapiens 188-195 22204857-7 2013 Interestingly, rosuvastatin therapy significantly increased fasting insulin (mean % changes; 28%, P=0.005). Rosuvastatin Calcium 15-27 insulin Homo sapiens 68-75 22658255-1 2012 OBJECTIVE: We evaluated the long-term effects of rosuvastatin and simvastatin on insulin sensitivity and secretion in patients with well-controlled type 2 diabetes. Rosuvastatin Calcium 49-61 insulin Homo sapiens 81-88 23489530-1 2013 OBJECTIVES: The objective of this substudy of the ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trial was to examine the association between insulin resistance and progression of left ventricular hypertrophy (LVH) in patients with aortic stenosis (AS). Rosuvastatin Calcium 124-136 insulin Homo sapiens 183-190 23678475-2 2013 The purpose of this study was to evaluate the effects of rosuvastatin on insulin resistance and adiponectin in patients with mild to moderate hypertension. Rosuvastatin Calcium 57-69 insulin Homo sapiens 73-80 22658255-11 2012 CONCLUSIONS: In well-controlled type 2 diabetic patients both rosuvastatin and simvastatin significantly impaired glycemic control and insulin secretion, without affecting insulin sensitivity. Rosuvastatin Calcium 62-74 insulin Homo sapiens 135-142 19459810-0 2009 The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients. Rosuvastatin Calcium 14-26 insulin Homo sapiens 30-37 21995692-0 2011 Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Rosuvastatin Calcium 45-57 insulin Homo sapiens 101-108 21995692-12 2011 CONCLUSION: To the extent that simvastatin 40 mg, rosuvastatin 10 mg and simvastatin/ezetimibe 10/10 mg are associated with adverse effects on insulin resistance, they appear to be of the same magnitude. Rosuvastatin Calcium 50-62 insulin Homo sapiens 143-150 21257003-2 2011 Our purpose was to compare the effects of maximum doses of rosuvastatin and atorvastatin on the plasma levels of the insulin, glycated albumin, adiponectin, and C-reactive protein compared to baseline in hyperlipidemic patients. Rosuvastatin Calcium 59-71 insulin Homo sapiens 117-124 21257003-5 2011 Atorvastatin and rosuvastatin at the maximum dosage both significantly (p <0.05) increased the median insulin levels by 5.2% and 8.7%, respectively, from baseline. Rosuvastatin Calcium 17-29 insulin Homo sapiens 105-112 21257003-9 2011 In conclusion, our data have indicated that the maximum dosage of atorvastatin or rosuvastatin therapy significantly lower C-reactive protein levels but also moderately increase insulin levels. Rosuvastatin Calcium 82-94 insulin Homo sapiens 178-185 19691613-0 2009 Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Rosuvastatin Calcium 0-12 insulin Homo sapiens 57-64 19691613-8 2009 CONCLUSION: In patients with IFG and hyperlipidaemia, rosuvastatin treatment was associated with a dose-dependent increase in insulin resistance. Rosuvastatin Calcium 54-66 insulin Homo sapiens 126-133 18585701-0 2008 Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Rosuvastatin Calcium 137-149 insulin Homo sapiens 33-40 18585701-8 2008 Stepwise multivariate linear regression analysis revealed that baseline triglyceride levels (R(2)=0.29, P=0.001) followed by baseline insulin resistance as assessed by the HOmeostasis Model Assessment (HOMA) (R(2)=0.25, P=0.001) were independently associated with the rosuvastatin-induced increase in the mean LDL particle size. Rosuvastatin Calcium 268-280 insulin Homo sapiens 134-141 18093597-0 2008 Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Rosuvastatin Calcium 10-22 insulin Homo sapiens 26-33 18093597-2 2008 Here, we provide evidence that rosuvastatin treatment of insulin resistant hamsters can induce improvements in hepatic and whole body insulin sensitivity. Rosuvastatin Calcium 31-43 insulin Homo sapiens 57-64 18093597-2 2008 Here, we provide evidence that rosuvastatin treatment of insulin resistant hamsters can induce improvements in hepatic and whole body insulin sensitivity. Rosuvastatin Calcium 31-43 insulin Homo sapiens 134-141 18093597-3 2008 Treatment with 10 mg/kg/day rosuvastatin for 10 days significantly reduced fasting insulin (-59%) and triglyceride (-50%) levels in fructose-fed hamsters (p<0.05). Rosuvastatin Calcium 28-40 insulin Homo sapiens 83-90 18093597-6 2008 At the molecular level, significant increases in tyrosine-phosphorylation of the hepatic insulin receptor and IRS-1 were observed for rosuvastatin-treated hamsters (+37% and +58%, respectively) compared to fructose-fed controls following an intravenous (IV) bolus of insulin (p<0.05). Rosuvastatin Calcium 134-146 insulin Homo sapiens 89-96 16128862-0 2005 Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Rosuvastatin Calcium 10-22 insulin Homo sapiens 26-33 16197666-3 2005 Therefore, we tested in this study whether treatment of insulin resistant familial combined hyperlipidaemia (FCH) patients with a high dose (40 mg/day) of the potent rosuvastatin was able to improve endothelial function, without necessarily improving insulin sensitivity. Rosuvastatin Calcium 166-178 insulin Homo sapiens 56-63 16128862-2 2005 This study was designed to evaluate the effect of rosuvastatin on serum lipids and insulin sensitivity in nondiabetic subjects with familial combined hyperlipidaemia (FCH), a population characterized by decreased insulin sensitivity. Rosuvastatin Calcium 50-62 insulin Homo sapiens 83-90